Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Company Overview - Cytokinetics is a late-stage biopharmaceutical company specializing in muscle biology, focused on developing drug candidates for diseases that compromise muscle performance [3] - The company aims to improve patient lives through global access to innovative medicines [3] Upcoming Event - Robert I. Blum, President and CEO of Cytokinetics, will participate in a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 4:40 PM Eastern Time [1] Product Development - Cytokinetics is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial for obstructive hypertrophic cardiomyopathy (HCM) [3] - The company is also developing omecamtiv mecarbil for heart failure with severely reduced ejection fraction (HFrEF), CK-586 for heart failure with preserved ejection fraction (HFpEF), and CK-089 for specific muscular dystrophies and impaired skeletal muscle function [3]